History

2009

July	Announces Evaluation and Option Agreement with Cancer Innovations, Inc. for Therapeutic Monoclonal Antibodies Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
June	Announces FDA Acceptance of Investigational New Drug Application for MORAb-004, A Monoclonal Antibody for the Treatment of Cancer
May	Announces Manufacturing Services Agreement with Lonza Group LTD
March	Announces Collaboration with Human Genome Sciences to Discover, Develop and Commercialize Antibodies for Oncology and Immunology Announces FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer Announces Initiation of MORAb-009 Phase II Study in First-Line Treatment of Mesothelioma
January	Signs Collaboration with University Hospital Heidelberg to Develop Therapeutic Antibodies to Treat Cancer

December	Signs Collaboration with University of Pennsylvania to Develop Antibodies to Targets Present in Hypoxic Regions of Tumors to Treat Cancer
November	Receives Funding from Department of Defense to Support Development of Therapeutic Antibodies to Treat Against Biowarfare Pathogens
September	Signs Agreement with Pivotal BioSciences to Access New Antibody Technology to Improve Therapeutic Activity
August	Opens Clinical Sites in Europe to Expand Ph2 trial of MORAb-009 in 1st line Pancreatic Cancer
	Signs Collaboration/License Agreement with the National Cancer Institute to Develop Antibodies to a Prostate Cancer Target
June	Receives Funding from Department of Defense to Develop Antibodies to Treat Against Infectious Disease Agents
May	Establishes Collaboration with the National Institute of Allergy and Infectious Diseases to Develop Therapeutic Antibodies to Treat Against Infectious Pathogens
April	Receive Orphan Status from European Regulatory Authorities for Farletuzumab in Ovarian Cancer and MORAb-009 in Pancreatic Cancer
March	Signs Agreement with Human Monoclonal International Inc to License and Develop an Antibody to Treat Cancer
January	Signs Collaboration Agreement with the Ludwig Institute to Validate Disease Targets
	Signs License Agreement with the National Cancer Institute to Develop Therapeutic Antibodies to Prostate Cancer Target

December	Initiates MORAb-009 Randomized, Controlled Phase II Study in 1^st Line Pancreatic Cancer
October	Morphotek Receives Funding from the National Institute of Allergy and Infectious Diseases to Develop Therapeutic Antibodies against Biowarfare Agents
September	Morphotek Receives Funding from the U.S. Department of Defense to Develop Therapeutic Antibodies against Biowarfare Agents
May	Morphotek Signs Development and Clinical Supply Agreement with CMC Biopharmaceuticals A/S for Therapeutic Antibody to Treat Melanoma
April	Acquired by Eisai Corp.
February	Obtains Exclusive License from Micromet for Antibody to Treat Melanoma and Other Cancers

October

June

February

Raised $40 Million to Advance its Antibody Pipeline

Initiation of Phase II Clinical Trial for MORAb-003 in Ovarian Cancer

FDA Accepts IND Application for MORAb-009

December	Exclusive License Agreement Signed with the National Cancer Institute (MORAb-009)
September	Invitrogen Corporation Acquires Cell Line Optimization Service Business


February	FDA Accepts IND Application for MORAb-003
January	Development Grant Awarded by NCI

December	Exclusive License Agreement Signed with the Ludwig Institute for Cancer Research (MORAb-004)
November	Morphotek Named “2004 Technology Company of the Year”
September	CRADA Signed with USAMRIID
July	Cross License Agreement Signed with Protein Design Labs

February	Series C Funding Raises $26 MM

October

Manufacturing Agreement Signed with Baxter Healthcare

September	PA Governor Mark Schweiker Awards Pennsylvania Opportunity Grant to Morphotek
July	Morphotek Awarded US Army Grant
May	Morphotek Expands Operations and Relocates to 41,000 sq ft Facility in Exton, PA
April	Research Agreement Signed with the Ludwig Institute for Cancer Research (MORAb-003)
February	Research Agreement Signed with the Wistar Institute


August	Series B Funding Round Raises $10MM

November	Company’s Scientific Advisory Board Established
July	Company’s Board of Directors Established
May	Morphotek is Founded by Drs. Luigi Grasso, Nicholas Nicolaides and Phillip Sass